Mirtazapine for Methamphetamine Use Disorder: Drug-Drug Interaction Study

Dr. Rush will collaborate with Dr. Coffin and Heluna Health to conduct a drug-drug interaction (DDI) study of mirtazapine for methamphetamine use disorder to ensure the safety of this medication for people actively-using methamphetamine (meth). The specific aims of this study are: *To determine if mirtazapine 30 mg daily alters the cardiovascular response to IV meth. The interaction of active medication (compared with placebo) with relevant doses of meth (30 mg) on cardiovascular (heart rate, blood pressure) parameters will be assessed to gather safety information in the Phase I human laboratory. *To determine if mirtazapine alters the pharmacokinetics of IV meth. Pharmacokinetic parameters for meth and its major metabolites will be assessed over 48 hours under steady state mirtazapine (30 mg) and relevant IV meth challenge (30 mg). *To evaluate the above aims in the setting of concomitant administration of morphine or methadone. Three DDI studies will be run simultaneously to evaluate the safety of mirtazapine in persons using both opioids and meth.